As of November 14, 2026, LeonaBio, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 19, 2026 (Form 8-K, March 19, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like LeonaBio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
LeonaBio, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-19. Every row below is cited to the filing it comes from, and this page adds each new change as LeonaBio, Inc. files it.
Layoffs on record: about 49 jobs, latest 2024-09-17 (layoff filings and notices).
Also on the record for LeonaBio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G, by Spruce Street Capital LP | 4.2% of the class | 5%+ stakes | Source |
| November 4, 2026 | Stake report, Schedule 13G, by Great Point Partners, LLC | 5.03% of the class | 5%+ stakes | Source |
| October 28, 2026 | Stake report, Schedule 13D/A, by Sermonix Pharmaceuticals, Inc. | 25.1% of the class | 5%+ stakes | Source |
| October 26, 2026 | Stake report, Schedule 13D/A, by Perceptive Advisors LLC | 19.99% of the class | 5%+ stakes | Source |
| August 31, 2026 | Stake report, Schedule 13D, by Sermonix Pharmaceuticals, Inc. | 36.9% of the class | 5%+ stakes | Source |
| August 25, 2026 | Stake report, Schedule 13D/A, by Perceptive Advisors LLC | 19.99% of the class | 5%+ stakes | Source |
| August 20, 2026 | Stake report, Schedule 13G/A, by Anders Hove | 12.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 7.7% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13D/A, by Perceptive Advisors LLC | 19.99% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G/A, by Baselake Partners, LP | 1.9% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13D/A, by Perceptive Advisors LLC | 19.99% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G/A, by Anders Hove | 6.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs LeonaBio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on LeonaBio, Inc. and the records around it.
LeonaBio, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Oliveira Steven Michael also filed stake reports on 1 other company: Forte Biosciences, Inc. (Jan 2026)
- ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Karyopharm Therapeutics Inc. (Oct 2026), enGene Therapeutics Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026)
- Spruce Street Capital LP also filed stake reports on 5 other companies: Entera Bio Ltd. (Nov 2026), Research Alliance Corp IV (Nov 2026), Yarrow Bioscience, Inc. (Nov 2026)
Watch LeonaBio, Inc.
Get an email when LeonaBio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on LeonaBio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on LeonaBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on LeonaBio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 18 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-19 | Reported | not named in the filing | 8-K, 2026-03-19 |
New leaders reset buying decisions — get the Full Report on LeonaBio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at LeonaBio, Inc., with the record behind each one.
Find candidates like senior executive at LeonaBio, Inc.Every change, in the filing's words
Reported
There will be no further grants under the Company's prior company-wide equity plan, the 2020 Equity Incentive Plan (the "2020 Plan"), which terminated for future use upon stockholder approval of the 2026 Plan.
- The Company's board of directors (the "Board") previously approved, subject to stockholder approval, the Company's 2026 Equity Incentive Plan (the "2026 Plan").
- At the Special Meeting, the Company's stockholders approved the 2026 Plan.
- Termination of the 2020 Plan will not affect outstanding awards previously issued pursuant to the 2020 Plan.
- The purposes of the 2026 Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors, and consultants, and to promote the success of the Company's business.
- These incentives are provided through the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, and performance awards as the administrator of the 2026 Plan may determine.
- Subject to adjustment upon changes in capitalization of the Company as provided in the 2026 Plan, up to 5,700,000 shares may be issued under the 2026 Plan.
- For additional information regarding the 2026 Plan, please refer to Proposal 4 of the Company's definitive proxy statement filed with the United States Securities and Exchange Commission on February 23, 2026, as amended on March 10, 2026 (together, the "Proxy Statement").
Tools for this story
Each opens in a new tab, filled in for LeonaBio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
